Results from phase II clinical trials indicated that, when combined with chemoradiotherapy, losartan significantly reduced the number of immunosuppressive regulatory T cells and FOXP3+ tumor cells within PDAC lesions, increased the infiltration of anti-tumor CD8+ T cells, and readjusted the immunosuppressive micro-environment (38). Here, FOXP3 is linked to neoplasm.